The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy

Metabolism: Clinical and Experimental

Volumn 62, Issue SUPPL.1, 2013, Pages

  Manson, Joann E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Clinical decision making; Estrogen; Genomics; Menopausal hormone therapy; Personalized medicine; Progestogen; Risk stratification

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; D DIMER; ESTROGEN; GELATINASE B; GESTAGEN; GLYCOPROTEIN IIIA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

AGE DISTRIBUTION; CANCER RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; DIET RESTRICTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ESTROGEN THERAPY; GENETIC PREDISPOSITION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYMPTOM; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

EID: 84870533682     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.08.015     Document Type: Article

References (27)

1. North American Menopause Society Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society Menopause 17 2010 242 255
2. R.J. Santen, D.C. Allred, S.P. Ardoin, D.F. Archer, N. Boyd, and G.D. Braunstein Postmenopausal hormone therapy: an Endocrine Society scientific statement J Clin Endocrinol Metab 95 2010 S1 66
3. Manson JE, Bassuk SS. The menopause transition and postmenopausal hormone therapy. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jamison JL, Loscalzo J, eds. Harrison's principles of internal medicine: McGraw-Hill, 2011.
4. International Menopause Society Aging, menopause, cardiovascular disease and HRT. International Menopause Society Consensus Statement Climacteric 12 2009 368 377
5. J.E. Rossouw, R.L. Prentice, J.E. Manson, L. Wu, D. Barad, V.M. Barnabei, M. Ko, A.Z. LaCroix, K.L. Margolis, and M.L. Stefanick Effects of postmenopausal hormone therapy on cardiovascular disease by age and years since menopause JAMA 297 2007 1465 1477
6. J.E. Manson, and S.S. Bassuk Invited commentary. Hormone therapy and risk of coronary heart disease: why renew the focus on the early years of menopause? Am J Epidemiol 166 2007 511 517
7. P.F. Bray, J.C. Larson, A.Z. Lacroix, J. Manson, M.C. Limacher, J.E. Rossouw, N.L. Lasser, W.E. Lawson, M.L. Stefanick, R.D. Langer, and K.L. Margolis Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events Am J Cardiol 101 2008 1599 1605
8. M.E. Mendelsohn, and R.H. Karas Molecular and cellular basis of cardiovascular gender differences Science 308 2005 1583 1587
9. F. Grodstein, T.B. Clarkson, and J.E. Manson Understanding the divergent data on postmenopausal hormone therapy N Engl J Med 348 2003 645 650
10. Women's Health Initiative Study Group Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group Control Clin Trials 19 1998 61 109
11. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
12. Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
13. J.E. Manson, J. Hsia, K.C. Johnson, J.E. Rossouw, A.R. Assaf, N.L. Lasser, M. Trevisan, H.R. Black, S.R. Heckbert, R. Detrano, O.L. Strickland, N.D. Wong, J.R. Crouse, E. Stein, and M. Cushman Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
14. J. Hsia, R.D. Langer, J.E. Manson, L. Kuller, K.C. Johnson, S.L. Hendrix, M. Pettinger, S.R. Heckbert, N. Greep, S. Crawford, C.B. Eaton, J.B. Kostis, P. Caralis, and R. Prentice Conjugated equine estrogens and the risk of coronary heart disease: the Women's Health Initiative Arch Intern Med 166 2006 357 365
15. M. Cushman, L.H. Kuller, R. Prentice, R.J. Rodabough, B.M. Psaty, R.S. Stafford, S. Sidney, and F.R. Rosendaal Estrogen plus progestin and risk of venous thrombosis JAMA 292 2004 1573 1580
16. M. Canonico, E. Oger, G. Plu-Bureau, J. Conard, G. Meyer, H. Levesque, N. Trillot, M.T. Barrellier, D. Wahl, J. Emmerich, and P.Y. Scarabin Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study Circulation 115 2007 840 845
17. A.Z. LaCroix, R.T. Chlebowski, J.E. Manson, A.K. Aragaki, K.C. Johnson, L. Martin, K.L. Margolis, M.L. Stefanick, R. Brzyski, J.D. Curb, B.V. Howard, C.E. Lewis, and J. Wactawski-Wende Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial JAMA 305 2011 1305 1314
18. S. Wassertheil-Smoller, S.L. Hendrix, M. Limacher, G. Heiss, C. Kooperberg, A. Baird, T. Kotchen, J.D. Curb, H. Black, J.E. Rossouw, A. Aragaki, M. Safford, E. Stein, S. Laowattana, and W.J. Mysiw Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial JAMA 289 2003 2673 2684
19. J.D. Curb, R.L. Prentice, P.F. Bray, R.D. Langer, L. Van Horn, V.M. Barnabei, M.J. Bloch, M.G. Cyr, M. Gass, L. Lepine, R.J. Rodabough, S. Sidney, G.I. Uwaifo, and F.R. Rosendaal Venous thrombosis and conjugated equine estrogen in women without a uterus Arch Intern Med 166 2006 772 780
20. J.E. Rossouw, M. Cushman, and P. Greenland Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy Arch Intern Med 168 2008 2245 2253
21. C. Carpeggiani, M. Cocean, and P. Landi ABO blood group alleles: a risk factor for coronary artery disease An angiographic study. Atherosclerosis 211 2010 461 466
22. J.E. Rossouw, P. Bray, and J. Liu Estrogen receptor polymorphisms and the vascular effects of hormone therapy Arterioscler Thromb Vasc Biol 31 2011 464 469
23. V.M. Barnabei, B.B. Cochrane, A.K. Aragaki, I. Nygaard, R.S. Williams, P.G. McGovern, R.L. Young, E.C. Wells, M.J. O'Sullivan, B. Chen, R. Schenken, and S.R. Johnson Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative Obstet Gynecol 105 2005 1063 1073
24. J.K. Ockene, D.H. Barad, B.B. Cochrane, J.C. Larson, M. Gass, S. Wassertheil-Smoller, J.E. Manson, V.M. Barnabei, D.S. Lane, R.G. Brzyski, M.C. Rosal, J. Wylie-Rosett, and J. Hays Symptom experience after discontinuing use of estrogen plus progestin JAMA 294 2005 183 193
25. J. Hays, J.K. Ockene, R.L. Brunner, J.M. Kotchen, J.E. Manson, R.E. Patterson, A.K. Aragaki, S.A. Shumaker, R.G. Brzyski, A.Z. LaCroix, I.A. Granek, and B.G. Valanis Effects of estrogen plus progestin on health-related quality of life N Engl J Med 348 2003 1839 1854
26. R.L. Brunner, M. Gass, A. Aragaki, J. Hays, I. Granek, N. Woods, E. Mason, R. Brzyski, J. Ockene, A. Assaf, A. LaCroix, K. Matthews, and R. Wallace Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial Arch Intern Med 165 2005 1976 1986
27. R.L. Brunner, A. Aragaki, V. Barnabei, B.B. Cochrane, M. Gass, S. Hendrix, D. Lane, J. Ockene, N.F. Woods, S. Yasmeen, and M. Stefanick Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial Menopause 17 2010 946 954